$32,878.13 ownership Payment -- Novartis Pharmaceuticals to Dr. Thomas Miller
Ophthalmologist Thomas Miller Receives $32,878 Ownership Stake in Novartis Pharmaceuticals
This page provides a detailed analysis of a $32,878.13 ownership payment from Novartis Pharmaceuticals to Dr. Thomas Miller. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $32,878.13 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Thomas Miller |
| NPI Number | 1321977966 |
| Physician Specialty | Ophthalmology |
| Location | City, IN |
| Date of Payment | 2024-05-08 |
| Related Drug/Device | Biktarvy |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $32.9K ownership payment to Thomas Miller, a Ophthalmology specialist in City, IN. The payment was associated with Biktarvy. Thomas Miller received a significant ownership interest payment of $32,878.13 from Novartis Pharmaceuticals. The payment is categorized as an 'Ownership or Investment Interest', indicating a financial stake rather than a service fee. This payment is associated with the drug Biktarvy, suggesting a potential link between the investment and the pharmaceutical's product.
Patient Guidance: What This Payment Means for You
This payment represents an ownership interest, not a direct payment for services. Consult with a financial advisor to understand its implications. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests can be complex and vary widely in ophthalmology; this specific amount should be evaluated against industry norms for similar investments.
Regulatory Context: Sunshine Act Requirements
Ownership interests must be disclosed under the Sunshine Act, and this record reflects that regulatory requirement.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- pharmaceutical-investment
- ophthalmology
- novartis-pharmaceuticals
- biktarvy
- physician-payment
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $32.9K payment for?
This was a ownership payment of $32.9K from Novartis Pharmaceuticals to Thomas Miller, categorized as "Ownership or Investment Interest". It was associated with Biktarvy. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Thomas Miller accept pharmaceutical money?
Yes, Thomas Miller received this $32.9K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Thomas Miller's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $32.9K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Thomas Miller's relationship with Novartis Pharmaceuticals?
The payment amount is substantial, exceeding typical consulting or speaking fees. This $32.9K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The 'ownership' nature of the payment is a key differentiator from other payment types.
What should patients do after learning about this payment?
This payment represents an ownership interest, not a direct payment for services. Consult with a financial advisor to understand its implications.
What else should I know about this ownership payment?
The specific drug Biktarvy is mentioned, which could be relevant to the ophthalmology specialty.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.